Cantuzumab

Cantuzumab is a type of monoclonal antibody that was developed for the treatment of cancer. It is also known as Cantuzumab mertansine and was developed by Immunogen.

History

Cantuzumab was developed by the biotechnology company Immunogen. It was designed to target the CanAg antigen, which is found on the surface of many types of cancer cells, including colorectal cancer, pancreatic cancer, and non-small cell lung cancer.

Mechanism of Action

Cantuzumab works by binding to the CanAg antigen on the surface of cancer cells. This binding triggers the release of a toxic substance called maytansinoid, which kills the cancer cells.

Clinical Trials

Cantuzumab has been tested in several clinical trials. In a Phase I trial, it was found to be safe and well-tolerated. However, in a Phase II trial, it did not show significant efficacy in patients with colorectal cancer.

Side Effects

The most common side effects of Cantuzumab include nausea, vomiting, and diarrhea. Other side effects can include fatigue, anemia, and neutropenia.

Future Research

Future research on Cantuzumab may focus on its potential use in combination with other cancer treatments, or on its use in other types of cancer.

See Also

• Monoclonal antibodies
• Cancer treatment
• Clinical trials

Cantuzumab Resources
Latest articles Most recent articles Ongoing trials	Wikipedia